Opioid Overdose — ED Management

Key Points

• Respiratory depression is the defining immediate threat in opioid overdose; ventilation takes priority over obtaining a complete drug history.
• A patient with a pulse and inadequate breathing should receive airway support, assisted ventilation, and an opioid antagonist without delaying basic resuscitation.
• In cardiac arrest, high-quality CPR and standard advanced life support remain the priority; naloxone must not interrupt proven resuscitation measures.
• Naloxone should be titrated to restore effective breathing and protective airway reflexes rather than to force complete wakefulness.
• Repeated naloxone doses may be required, especially with potent synthetic opioids or when intranasal or intramuscular routes are used.
• Recurrent respiratory depression can occur after initial reversal because many opioids outlast naloxone.
• Incomplete awakening after adequate naloxone does not exclude opioid poisoning and should prompt evaluation for coingestants, hypoxic injury, trauma, or nonopioid adulterants.
• Routine urine drug screening is not required to treat a clinically apparent overdose and may not detect fentanyl or other synthetic opioids.
• Discharge requires low risk of recurrent respiratory depression, normal vital signs, normal consciousness, overdose education, and access to take-home naloxone.
• An overdose encounter is a major opportunity to diagnose opioid use disorder and initiate or link the patient to medication treatment.

Algorithm

1. Assess responsiveness, breathing, and circulation immediately; activate emergency support and place the patient on continuous monitoring.
2. If there is no definite pulse, begin high-quality CPR and standard cardiac arrest care; consider naloxone only if it does not interrupt resuscitation.
3. If a pulse is present but breathing is inadequate, open the airway, provide oxygen as needed, and begin bag-mask ventilation.
4. Administer naloxone for suspected opioid-associated respiratory depression and repeat every 2 to 3 minutes as needed while ventilation continues.
5. Reassess respiratory rate, tidal volume, oxygenation, end-tidal carbon dioxide when available, mental status, airway reflexes, blood pressure, and heart rate.
6. If ventilation cannot be maintained or airway protection remains inadequate, proceed to definitive airway management.
7. Check point-of-care glucose and obtain targeted testing for coingestants, complications, or alternative diagnoses based on history and examination.
8. If respiratory depression recurs, repeat naloxone; when repeated effective boluses are required, consider a continuous naloxone infusion.
9. Observe until recurrent toxicity is unlikely and consciousness and vital signs have normalized; admit patients with high-risk exposure or complications.
10. Before discharge, provide naloxone, overdose-response education, harm-reduction counseling, and evaluation and treatment linkage for opioid use disorder.

Clinical Synopsis & Reasoning

Opioid overdose should be suspected when depressed consciousness is accompanied by slow, shallow, irregular, or absent respirations. Miosis is common but is not required, particularly after severe hypoxia, with mixed-drug exposure, or when other neurologic processes are present. The immediate threat is loss of ventilation, which causes hypoxemia, hypercapnia, aspiration risk, progressive acidosis, cardiac arrest, and death. Clinical reasoning therefore begins with respiratory status rather than with a search for a specific opioid. A patient with a definite pulse but inadequate breathing needs airway opening and assisted ventilation immediately while naloxone is prepared. If there is no definite pulse, manage cardiac arrest with high-quality CPR and standard advanced life support; naloxone may be given when opioid poisoning is suspected, but it must not interrupt proven resuscitation measures.

History should establish the substance when known, route, estimated dose, time of exposure, whether the product was prescribed or obtained from an unregulated supply, prior naloxone doses, response to those doses, and possible coingestants. Long-acting opioids, methadone, sustained-release preparations, large oral ingestions, fentanyl analog exposure, and body-packing or body-stuffing situations can produce prolonged or recurrent toxicity. Alcohol, benzodiazepines, gabapentinoids, sedating antihistamines, antipsychotics, and other central nervous system depressants can worsen respiratory compromise and may explain incomplete awakening after naloxone. The contemporary unregulated opioid supply also contains nonopioid sedatives such as xylazine and medetomidine. Naloxone should still be administered because fentanyl or another opioid is commonly present, but persistent sedation, bradycardia, or hypotension after adequate reversal should prompt consideration of these coexposures and continued supportive care.

A clinically meaningful response to naloxone supports an opioid contribution but is not a stand-alone diagnostic test. Failure to awaken fully does not exclude opioid poisoning if ventilation improves. Likewise, a patient who remains obtunded despite restoration of breathing requires evaluation for other causes such as head trauma, intracranial hemorrhage, postictal state, hypoglycemia, sedative-hypnotic toxicity, clonidine or other alpha-2 agonist toxicity, carbon monoxide exposure, sepsis, or metabolic derangement. Routine urine drug screening rarely determines emergency treatment, and standard screens may not detect fentanyl or many synthetic opioids. Testing should therefore be driven by the clinical context and by findings that will change management.

Treatment Strategy & Disposition

Open the airway, suction secretions or emesis, provide supplemental oxygen when hypoxemic, and use bag-mask ventilation when spontaneous breathing is inadequate. Airway adjuncts and continuous pulse oximetry are useful, and capnography can detect hypoventilation before oxygen saturation falls. Endotracheal intubation is appropriate when effective oxygenation or ventilation cannot be maintained, when airway reflexes remain unsafe despite reversal attempts, or when another process requires a definitive airway. Naloxone is an opioid receptor antagonist used to reverse opioid-induced respiratory depression. In life-threatening adult opioid poisoning, the 2025 American Heart Association guideline lists 0.2 to 2 mg by IV, IO, or IM routes or 2 to 4 mg intranasally, repeated every 2 to 3 minutes as needed. The treatment target is adequate ventilation and restoration of protective airway reflexes, not necessarily complete alertness. In a monitored patient with a pulse who is still breathing and is known or suspected to be opioid dependent, clinicians often begin at the lower end of the dosing range and titrate to limit severe precipitated withdrawal. In apnea, severe hypoxemia, or rapidly deteriorating ventilation, reversal should not be delayed by overly cautious dose titration.

Recurrent respiratory depression is common when the duration of the opioid exceeds the duration of naloxone. Repeat bolus doses can be given, and patients who repeatedly relapse after an effective dose may benefit from a naloxone infusion, commonly started at approximately two thirds of the total effective waking dose per hour and titrated to respiratory status. Ventilation remains the immediate rescue measure if respiratory depression returns while the infusion is being prepared. Treat complications directly. Aspiration may require oxygen, ventilatory support, imaging, and treatment for aspiration pneumonia when a true bacterial infection develops. Noncardiogenic pulmonary edema can occur after opioid overdose and has also been reported after reversal; manage it according to oxygenation and respiratory mechanics rather than assuming naloxone itself is the sole cause. Prolonged immobilization can cause rhabdomyolysis, pressure injury, and compartment syndrome. Hypothermia, trauma, hypoglycemia, and occult coingestion should be corrected or treated when present.

Observation is individualized rather than based on a single universal time cutoff. The 2025 AHA guideline recommends observation in a health care setting until the patient is at low risk for recurrent respiratory depression and has normal vital signs and a normal level of consciousness. Longer monitoring or admission is appropriate after long-acting or sustained-release opioid exposure, repeated naloxone requirements, naloxone infusion, uncertain ingestion, persistent hypoxemia, aspiration, pulmonary edema, significant coingestants, trauma, suicidal intent, pregnancy complications, or prolonged sedation from nonopioid adulterants. Before discharge, provide naloxone and overdose-response teaching. Screen for opioid use disorder and offer evidence-based treatment. Buprenorphine can be initiated in the emergency department after acute intoxication has resolved and objective opioid withdrawal is present, using an institutionally appropriate induction protocol and linkage to ongoing care.

Epidemiology / Risk Factors

• Opioid overdose remains a major cause of preventable death in the United States, with illegally manufactured fentanyl involved in a large proportion of fatal events.
• Risk rises after a period of reduced tolerance, including release from incarceration, detoxification, hospitalization, or a period of abstinence followed by return to use.
• Concurrent use of benzodiazepines, alcohol, sedating medications, or other respiratory depressants increases the risk of severe poisoning.
• People with prior overdose, opioid use disorder, high-dose opioid exposure, or use of an unpredictable unregulated drug supply are at particularly high risk for recurrence.
• Xylazine and medetomidine are examples of nonopioid sedatives detected in the contemporary drug supply that can complicate the expected response to naloxone.
• Survival from an overdose does not remove future risk; the period after a nonfatal overdose is an important window for prevention and treatment engagement.

Investigations

Naloxone Options

Pharmacology

Prognosis / Complications

• Patients who receive rapid ventilation and opioid reversal before prolonged hypoxemia often recover fully.
• Prognosis worsens with delayed discovery, prolonged apnea, cardiac arrest, aspiration, severe hypoxic brain injury, major trauma, or toxic coingestants.
• Recurrent respiratory depression is a major near-term hazard when the opioid is long acting, sustained release, very high dose, or incompletely characterized.
• Persistent altered mental status after respiratory recovery raises concern for coingestion, nonopioid adulterants, intracranial pathology, seizure, metabolic disease, or hypoxic injury.
• Nonfatal overdose strongly predicts future overdose risk, making treatment of opioid use disorder and access to naloxone core components of secondary prevention.
• Engagement with medications for opioid use disorder, particularly buprenorphine or methadone, substantially improves long-term treatment outcomes compared with referral alone.

Patient Education / Counseling

• Explain that naloxone reverses the opioid component of an overdose but does not replace emergency evaluation, rescue breathing, or CPR when those are needed.
• Teach the patient, family, or other likely witnesses how to recognize slow or absent breathing, administer naloxone, call emergency services, provide rescue breathing or CPR as trained, and repeat naloxone when needed.
• Emphasize that a person can become sedated again after initially waking because naloxone may wear off before the opioid does.
• Advise against using opioids alone and discuss the added danger of combining opioids with benzodiazepines, alcohol, or other sedatives.
• Discuss the unpredictability of the unregulated drug supply, including fentanyl and nonopioid adulterants, and the fact that persistent sedation after naloxone can still require emergency care.
• Offer take-home naloxone or prescribe it at discharge when direct dispensing is not available.
• Screen for opioid use disorder without stigmatizing language and offer buprenorphine initiation or a direct treatment connection when clinically appropriate.
• Provide clear return precautions for recurrent sleepiness, slowed breathing, chest pain, persistent vomiting, severe withdrawal, fever, new neurologic symptoms, worsening wounds, or any concern for another overdose.

Notes

Current resuscitation guidance emphasizes that airway support and ventilation are the immediate life-saving interventions in severe opioid poisoning. Naloxone is an adjunct to those measures, not a substitute for them. The practical endpoint is adequate spontaneous ventilation and airway protection. A patient who remains sleepy but is breathing effectively may not need escalating naloxone solely to become fully alert, whereas a patient with apnea or severe hypoventilation requires prompt and repeated reversal while ventilation continues.

The drug supply is evolving. Xylazine and medetomidine can produce prolonged sedation, bradycardia, and hypotension that naloxone does not directly reverse. Naloxone should still be given when opioid exposure is possible because fentanyl or another opioid is often co-present. Persistent sedation after the respiratory component improves should trigger supportive care and evaluation for nonopioid sedatives rather than endless naloxone escalation. In April 2026, the CDC specifically advised clinicians to consider medetomidine in suspected opioid overdoses with prolonged sedation after adequate opioid reversal.

Discharge planning is part of emergency treatment. The 2025 American Heart Association guidance recommends providing an opioid antagonist and teaching at discharge after treatment for opioid overdose. Whenever possible, the emergency visit should also be used to identify opioid use disorder, discuss medications for opioid use disorder, and create a direct connection to ongoing care. Buprenorphine initiation in the emergency department is supported by evidence showing improved treatment engagement compared with referral alone. Local protocols should determine induction strategy, follow-up arrangements, and management of patients exposed to fentanyl or other long-acting opioids.

References

1. American Heart Association 2025 Guidelines: Adult and Pediatric Special Circumstances of Resuscitation — Link
2. CDC: Lifesaving Naloxone — Link
3. CDC Health Advisory: Medetomidine in the U.S. Illegal Fentanyl Supply — Link
4. NIDA: Initiating Buprenorphine Treatment in the Emergency Department — Link
5. SAMHSA: Overdose Prevention and Response Toolkit — Link